TScan Therapeutics Pivots to In Vivo TCR-T Therapy, Halting Allogeneic Cell Program TSC-101 Amidst Manufacturing Challenges

September 6, 2026

FirstWord Pharma USA

Overview

TScan Therapeutics announced a strategic pivot, discontinuing its lead allogeneic cell therapy program, TSC-101, and shifting focus to preclinical in vivo TCR-T candidates for solid tumors, citing funding constraints and the high cost/difficulty of in-house manufacturing. The company previously evaluated Cellares’ Cell Shuttle for automated production, noting Bristol Myers Squibb’s termination of a manufacturing agreement with Cellares due to CAR-T commercial scale issues. This move underscores persistent challenges in manufacturing costs and scalability for ex vivo autologous cell therapies.

In Depth

Key Findings

TScan Therapeutics has announced a significant strategic shift, discontinuing its lead allogeneic cell therapy program, TSC-101, and re-focusing its efforts on preclinical in vivo TCR-T (T-cell receptor engineered T-cell) candidates for solid tumors. This decision stems from funding challenges and the inherent high costs and complexities associated with traditional ex vivo cell therapy manufacturing, particularly for autologous approaches. This pivot signals a clear recognition of the manufacturing bottlenecks confronting the cell therapy industry and a proactive search for more efficient therapeutic modalities.

Technical/Clinical Details

Discontinuation of TSC-101 Program: TScan’s allogeneic cell therapy candidate, TSC-101, designed to target specific cancer antigens, was halted primarily due to financial constraints and manufacturing difficulties. While allogeneic cell therapies are theoretically ‘off-the-shelf,’ offering potential cost efficiencies, their actual production still demands complex processes and stringent quality control.
Pivot to In Vivo TCR-T: The company’s new focus is on in vivo TCR-T therapy, where TCR-T cells are generated and expanded within the patient’s body. This approach could eliminate the need for complex ex vivo cell manipulation and culture steps, potentially leading to substantial reductions in manufacturing costs and timelines. Targeting solid tumors with this modality holds significant clinical implications.
Implications of Cellares’ Partnership: TScan had previously evaluated Cellares’ Cell Shuttle platform for automated production. However, the recent termination of Bristol Myers Squibb’s manufacturing agreement with Cellares, citing issues with CAR-T (Chimeric Antigen Receptor T-cell) commercial production (e.g., high manufacturing costs, production timelines, and quality consistency), suggests that even advanced automation technologies face deep-seated challenges in cell therapy manufacturing.
Cost and Scalability Challenges: Autologous cell therapies, which involve individualized processing of each patient’s cells, inherently face very high manufacturing costs and difficulties in scaling up production. Consequently, cell therapy developers are increasingly exploring process simplification and transitions to in vivo approaches.

Background & Context

While cell therapies, particularly CAR-T therapies, have achieved groundbreaking successes in hematological cancers, their widespread adoption is hampered by exorbitant treatment costs and complex manufacturing processes. Manufacturing costs often run into hundreds of thousands of dollars, imposing a significant burden on healthcare systems and patients. Underlying these costs are factors such as stringent GMP standards, the need for highly skilled personnel, and supply chain complexities. TScan’s strategic shift can be understood as part of a broader industry movement to overcome this ‘manufacturing wall.’

Strategic Significance & Outlook

TScan’s strategic pivot to in vivo TCR-T therapy represents a novel approach to improving manufacturing efficiency and reducing costs within the cell therapy sector. If the in vivo approach can demonstrate efficacy and safety in solid tumors, it could prove to be a game-changer for cell therapies. Investors will likely be drawn to companies and technologies that can offer more scalable and cost-effective manufacturing solutions compared to traditional ex vivo production. This move may also prompt a re-evaluation of the entire cell therapy supply chain, accelerating investments in new manufacturing technologies and platforms.

Source: https://firstwordpharma.com/story/7941531

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.